, Volume 82, Issue 4, pp 777–789 | Cite as

Kinetic Degradation Study of Dapagliflozin Coupled with UHPLC Separation in the Presence of Major Degradation Product and Metformin

  • Wafaa A. Zaghary
  • Shereen Mowaka
  • Moataz S. HendyEmail author


A novel ultra-performance liquid chromatography with UV detector technique was established for simultaneous determination of two antidiabetic drugs, dapagliflozin (DAPA) and metformin (MET), followed by a stress degradation study. Main degradation product was chromatographically separated and precisely characterized via LC-MS/MS. Chromatographic separation done on a Symmetry® Acclaim™ RSLC 120 C18 column (100 mm, 2.1 mm, 2.2 µm), column temperature was maintained at 60 °C. Mobile phase was a mixture of potassium dihydrogen phosphate buffer, pH (3.5)—acetonitrile (50:50, v/v) at flow rate of 0.4 mL/min. The method has displayed an adequate detection at concentration ranges of 1–50 µg/mL for dapagliflozin propanediol monohydrate and 0.5–100 µg/mL for metformin hydrochloride. DAPA was then exposed to different stress conditions include alkaline, acidic, oxidative and ultraviolet light. A study of the degradation kinetics in alkaline medium for DAPA has proved that the degradation follows a pseudo-first-order reaction. The proposed method was effectively applied for the analysis of laboratory prepared mixtures as well as a combined pharmaceutical formulation with 1:200 ratio of DAPA: MET. No significant difference was found regarding accuracy and precision upon statistical comparison between the obtained results and those of the reported method. Validation was conducted in compliance with the ICH guidelines proving that method is selective, linear, precise and accurate. The simplicity and sensitivity of this method allows its use in the quality control tests of the two cited drugs.

Graphical Abstract


Dapagliflozin Metformin Degradation kinetics SGLT2 Xigduo XR Stability study HPLC–UV UHPLC–UV 



This study was self-funded, no fund is received.

Compliance with ethical standards

Conflict of interest

No conflict of interest of any kind.

Research involving human or animal participants

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Rojas L, Gomes M (2013) Diabetol Metab Syndr 5:1–15CrossRefGoogle Scholar
  2. 2.
    Ahmed M (2010) Int J Diabetes Mellitus 2:125–126CrossRefGoogle Scholar
  3. 3.
    Jani B, Shah K, Kapupara P (2015) Int J Res Dev Pharm L Sci 4:1569–1576Google Scholar
  4. 4.
    Jani B, Shah V, Kapupara P (2015) J Bioequivalence Stud 1:1–7Google Scholar
  5. 5.
    Yunoos M, Sankar G (2015) Asian J Pharm Clin Res 8:320–326Google Scholar
  6. 6.
    Shyamala B, Nidhi M, Kavitha, Pooja, Sharma J (2015) Am J Biol Pharm Res 2:109–113Google Scholar
  7. 7.
    Deepan T (2017) Eur J Appl Sci 9:189–199Google Scholar
  8. 8.
    Chitra K, Eswaraiah C, Rao M (2015) J Chem Pharm Res 7:45–49Google Scholar
  9. 9.
    Sanagapati M, Dhanalakshmi K, Reddy G, Sreenivasa S (2014) J Adv Pharm Educ Res 4:350–353Google Scholar
  10. 10.
    Manasa S, Dhanalakshmi K, Reddy G, Kavitha B (2014) Int J Pharm Sci Rev Res 27:270–272Google Scholar
  11. 11.
    Manasa S, Dhanalakshmi K, Nagarjunareddy G, Sreenivasa S (2014) IJPSR 5:5394–5397Google Scholar
  12. 12.
    Sanagapati M, Dhanalakshmi K, Reddy G, Sreenivasa S (2014) Int J Pharm Sci Drug Res 6:250–252Google Scholar
  13. 13.
    Aubry H, Gu R, Magnier L, Morgan X, Xu M, Tirmenstein B, Wang Y, Deng J, Cai P, Couerbe, Arnold M (2010) Bioanalysis 2:2001–2009CrossRefPubMedGoogle Scholar
  14. 14.
    Bhushan R, Gupta D, Jain A (2006) J Planar Chromatogr Mod TLC 19:288–296CrossRefGoogle Scholar
  15. 15.
    Sengupta P, Bhaumik U, Ghosh A, Sarkar A, Chromatographia, 2009, 69, 1243–1250Google Scholar
  16. 16.
    Elbagary R, Elkady E, Ayoub B (2011) Int J Biomed Sci 7:201–208Google Scholar
  17. 17.
    Wang M, Miksa I (2007) J Chromatogr B: Biomed Sci Appl 856:318–327CrossRefGoogle Scholar
  18. 18.
    Georgita C, Albu F, David V, Medvedovici A (2007) J Chromatogr B 854:211–218CrossRefGoogle Scholar
  19. 19.
    Ali M, Rafiuddin S, Ghori M, Khatri A, Chromatographia, 2008, 67, 517–525Google Scholar
  20. 20.
    Lai E, Feng S (2006) J Chromatogr B 843:94–99CrossRefGoogle Scholar
  21. 21.
    Elbagary R, Elkady E, Ayoub B, Talanta, 2011, 85, 673–680Google Scholar
  22. 22.
    Zhang L, Tian Y, Zhang Z, Chen Y (2007) J Chromatogr B 854:91–98CrossRefGoogle Scholar
  23. 23.
    Ali H, Duraidi I, Saket M, Abu-Nameh E (2009) J AOAC Int 92:119–124PubMedGoogle Scholar
  24. 24.
    Elbagary R, Elkady E, Ayoub B (2013) Eur J Chem 4:360–365CrossRefGoogle Scholar
  25. 25.
    Ghassempour M, Ahmadi S, Ebrahimi, Aboul-Enein H, Chromatographia, 2006, 64, 101–104Google Scholar
  26. 26.
    Elbagary R, Elkady E, Ayoub B (2011) Int J Biomed Sci 7:62–69Google Scholar
  27. 27.
    Tahara K, Yonemoto A, Yoshiyama Y, Nakamura T, Aizawa M, Fujita Y, Nishikawa T (2006) Biomed Chromatogr 20:1200–1205CrossRefPubMedGoogle Scholar
  28. 28.
    Pawar S, Meshram G, Phadke M, Chromatographia, 2008, 68, 1063–1066Google Scholar
  29. 29.
    Elbagary R, Elkady E, Ayoub B (2013) Eur J Chem 4:444–449CrossRefGoogle Scholar
  30. 30.
    Mowaka S,., Ayoub B, Pharmazie, 2017, 72, 67–72PubMedGoogle Scholar
  31. 31.
    Mowaka S, Elkady E, Elmazar M, Ayoub B, Microchem J, 2017, 130, 360–365Google Scholar
  32. 32.
    Ayoub B, Abdel-Aziz O, Pharmazie, 2016, 71, 683–690PubMedGoogle Scholar
  33. 33.
    Ayoub B (2015) RSC Adv 5:95703–95709CrossRefGoogle Scholar
  34. 34.
    Mowaka S, Mohamed D (2015) RSC Adv 5:60467–60481CrossRefGoogle Scholar
  35. 35.
    Miller JN, Miller JC, Statistics and chemometrics for analytical chemistry, 5th edn, Pearson Education Limited, Harlow, 2005Google Scholar
  36. 36.
    ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology, Q2 (R1), Current step 4 version, Parent guidelines on Methodology, 1996, incorporated in November 2005Google Scholar
  37. 37.
    ICH Harmonised Tripartite Guidelines, Q1A (R2) Stability Testing of New Drug Substances and Products, 2003Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Pharmaceutical Chemistry Department, Faculty of PharmacyHelwan UniversityEin HelwanEgypt
  2. 2.Pharmaceutical Chemistry Department, Faculty of PharmacyThe British University in EgyptEl-SheroukEgypt
  3. 3.Analytical Chemistry Department, Faculty of PharmacyHelwan UniversityEin HelwanEgypt
  4. 4.The Center for Drug Research and Development (CDRD), Faculty of PharmacyThe British University in EgyptEl-SheroukEgypt

Personalised recommendations